PierianDx, which provides a range of molecular tests for clinical labs, says its services will be enhanced through this acquisition, given Tute Genomics’ leading constitutional and exome testing capabilities. PierianDx will maintain the Tute Genomics solution until the platforms are fully integrated in spring of 2017.
Although PierianDx plans to establish a development team in Tute Genomics’ former headquarters in Provo, the executive team — including Tute Genomics’ COO Andy Olson and Vice President of Product Development Bryce Daines — will relocate to St. Louis. Reid Robison, CEO of Tute Genomics, will join the PierianDx board of directors.
More articles on health IT:
Hays Medical Center upgrades to MEDITECH’s web-based EHR
Dapasoft launches clinical data integration engine Corolar Cloud
AHA launches MACRA implementation tool
